AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17982547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical and middle root canal thirds enlarged with nickel‐titanium Orifice Opener instruments (Group 2)
Number of subjects: 40
Study 17982547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical and middle root canal thirds enlarged with Gates‐Glidden drills (Group 3)
Number of subjects: 40
Study 17982547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical and middle root canal thirds enlarged with LA Axxess burs (Group 4)
Number of subjects: 40
Study 15744631 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract (612 mg)
Number of subjects: 241
Study 15744631 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (50 mg)
Number of subjects: 241
Study 11782871 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg/d
Number of subjects: 106
Study 11782871 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 600 mg/d
Number of subjects: 106
Study 11782871 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (both doses)
Number of subjects: 106
Study 9840235 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% LCT (Long Chain Triglycerides)
Number of subjects: 21
Study 9840235 — intervention group
Group type: COMPARATOR
Intervention: 20% 1:1 mixture of LCT/MCT (Medium Chain Triglycerides)
Number of subjects: 21
Study 9840235 — intervention group
Group type: COMPARATOR
Intervention: Comparison between LCT and LCT/MCT
Number of subjects: 21
Study 8307468 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate meal (74% of energy)
Number of subjects: 8
Study 8307468 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meal (71% of energy)
Number of subjects: 8
Study 8307468 — intervention group
Group type: COMPARATOR
Intervention: Comparison of high fat vs high carbohydrate meals
Number of subjects: 8
Study 2648911 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months of daily chemotherapy with streptomycin, isoniazid, rifampin, and pyrazinamide
Number of subjects: 1710
Study 2648911 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 months of chemotherapy (3 times a week)
Number of subjects: 1710
Study 2648911 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of daily chemotherapy with streptomycin, isoniazid, rifampin, and pyrazinamide
Number of subjects: 1710
Study 30097579 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-based attention intervention for 8 weeks
Number of subjects: 0
Study 30097579 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (ADHD-NI) group
Number of subjects: 0
Study 27138236 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 38
Study 27138236 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 38
Study 24279284 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured diabetes education plus insulin therapy
Number of subjects: 1511
Study 24279284 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus insulin therapy
Number of subjects: 1511
Study 22577038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg, administered 3 times daily for 3 days
Number of subjects: 150
Study 22577038 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg, administered 3 times daily for 3 days
Number of subjects: 150
Study 22577038 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered 3 times daily for 3 days
Number of subjects: 150
Study 20053952 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (20 trains of 40 pulses at 20 Hz, intensity 90% of resting motor threshold)
Number of subjects: 15
Study 20053952 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 15
Study 18176730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural team-based, individually geared, low-intensity rehabilitation programme
Number of subjects: 194
Study 18176730 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 194
Study 16023771 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwP vaccine injected in the buttock
Number of subjects: 0
Study 16023771 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine injected in the buttock
Number of subjects: 0
Study 16023771 — intervention group
Group type: COMPARATOR
Intervention: DTwP vaccine injected in the thigh
Number of subjects: 0
Study 16023771 — intervention group
Group type: COMPARATOR
Intervention: DTaP vaccine injected in the thigh
Number of subjects: 0
Study 12601115 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine loading test (Phe-L)
Number of subjects: 0
Study 9920951 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured cardiac-rehabilitation program (exercise group)
Number of subjects: 27
Study 8872499 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 200 mg/kg
Number of subjects: 21
Study 8872499 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 400 mg/kg
Number of subjects: 21
Study 8872499 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 600 mg/kg
Number of subjects: 21
Study 8497014 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (79 +/- 3% CHO)
Number of subjects: 18
Study 8497014 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal carbohydrate diet (47 +/- 8% CHO)
Number of subjects: 18
Study 8497014 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (12 +/- 1% CHO)
Number of subjects: 18
Study 8497014 — intervention group
Group type: COMPARATOR
Intervention: Trial 1 (baseline performance)
Number of subjects: 18
Study 8497014 — intervention group
Group type: COMPARATOR
Intervention: Trial 2 (after 24 h recovery)
Number of subjects: 18
Study 3623782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (23.8 g, 350 ml solution)
Number of subjects: 7
Study 3623782 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg, 350 ml solution)
Number of subjects: 7
Study 3623782 — intervention group
Group type: COMPARATOR
Intervention: Placebo (350 ml solution)
Number of subjects: 7
Study 30003794 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach letter and brochure recommending HPV vaccination followed by automated HPV vaccine reminders
Number of subjects: 1805
Study 30003794 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1805
Study 28705172 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant (20 mg od)
Number of subjects: 50
Study 28705172 — intervention group
Group type: COMPARATOR
Intervention: Orlistat (120 mg tds)
Number of subjects: 50
Study 28705172 — intervention group
Group type: COMPARATOR
Intervention: Metformin (500 mg tds)
Number of subjects: 50
Study 28705172 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (45 mg od)
Number of subjects: 50
Study 26410206 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental visual imagery (MVI) programme (n = 17)
Number of subjects: 40
Study 26410206 — intervention group
Group type: COMPARATOR
Intervention: Sham verbal programme (control group, n = 10)
Number of subjects: 40
Study 26410206 — intervention group
Group type: COMPARATOR
Intervention: No intervention (stability group, n = 13)
Number of subjects: 40
Study 24246434 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 198
Study 24246434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 20937544 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised nutrition support
Number of subjects: 132
Study 18826659 — intervention group
Group type: EXPERIMENTAL
Intervention: Available Fe intake
Number of subjects: 0
Study 18826659 — intervention group
Group type: EXPERIMENTAL
Intervention: Available Zn intake
Number of subjects: 0
Study 18826659 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 intake
Number of subjects: 0
Study 18826659 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin intake
Number of subjects: 0
Study 16495704 — intervention group
Group type: EXPERIMENTAL
Intervention: BALI model (4-variable prognostic model including BUN >or=25 mg/dL, Age >or=65 years, LDH >or=300 IU/L, IL‐6 >or=300 pg/mL)
Number of subjects: 0
Study 16495704 — intervention group
Group type: COMPARATOR
Intervention: Ranson scoring system
Number of subjects: 0
Study 16495704 — intervention group
Group type: COMPARATOR
Intervention: Glasgow scoring system
Number of subjects: 0
Study 16495704 — intervention group
Group type: COMPARATOR
Intervention: APACHE II scoring system
Number of subjects: 0
Study 16495704 — intervention group
Group type: EXPERIMENTAL
Intervention: BALI model
Number of subjects: 0
Study 15297138 — intervention group
Group type: COMPARATOR
Intervention: Standard conformal radiotherapy (CFRT) at 64 Gy
Number of subjects: 843
Study 15297138 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose conformal radiotherapy (CFRT) at 74 Gy
Number of subjects: 843
Study 10757254 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (45 mg or 90 mg)
Number of subjects: 24
Study 10757254 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg, 400 mg or 800 mg)
Number of subjects: 24
Study 10757254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10757254 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 24
Study 10757254 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 24
Study 8663871 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 667
Study 8663871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 667
Study 1758297 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk/jog training (W/J)
Number of subjects: 57
Study 1758297 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (STREN)
Number of subjects: 57
Study 1758297 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONT)
Number of subjects: 57
Study 6409208 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 78
Study 6409208 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 78
Study 6409208 — intervention group
Group type: COMPARATOR
Intervention: Thiazides (long-term treatment)
Number of subjects: 78
Study 6409208 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (substitution for thiazides in long-term treatment)
Number of subjects: 78
Study 31006767 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate‐nostril yoga breathing (ANYB)
Number of subjects: 50
Study 31006767 — intervention group
Group type: COMPARATOR
Intervention: Breath awareness (BAW)
Number of subjects: 50
Study 31006767 — intervention group
Group type: COMPARATOR
Intervention: Quiet sitting (QS)
Number of subjects: 50
Study 28679772 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of ≥1 CTC/7.5 mL before NT
Number of subjects: 213
Study 28679772 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of ≥2 CTCs/7.5 mL before NT
Number of subjects: 213
Study 28679772 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC-negative patients with pathologic complete response (pCR)
Number of subjects: 213
Study 28679772 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CTCs and less tumor response
Number of subjects: 213
Study 28679772 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of ≥2 CTCs/7.5 mL before NT in HER2-positive and triple-negative patients
Number of subjects: 213
Study 28679772 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCs detected after NT
Number of subjects: 213
Study 25835472 — intervention group
Group type: EXPERIMENTAL
Intervention: Panoply
Number of subjects: 166
Study 25835472 — intervention group
Group type: COMPARATOR
Intervention: Expressive Writing
Number of subjects: 166
Study 23402397 — intervention group
Group type: EXPERIMENTAL
Intervention: fotemustine and dacarbazine repeated on 3-week cycle
Number of subjects: 260
Study 23402397 — intervention group
Group type: COMPARATOR
Intervention: dacarbazine alone repeated on 3-week cycle
Number of subjects: 260
Study 23402397 — intervention group
Group type: EXPERIMENTAL
Intervention: fotemustine and dacarbazine plus IFN‐α2b three times per week
Number of subjects: 260
Study 23402397 — intervention group
Group type: COMPARATOR
Intervention: dacarbazine plus IFN‐α2b three times per week
Number of subjects: 260
Study 21511707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (c-tDCS) of left M1 for 20 minutes
Number of subjects: 13
Study 21511707 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS of left M1
Number of subjects: 13
Study 19675499 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (10 g Cr + 10 g dextrose)
Number of subjects: 42
Study 19675499 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) (20 g dextrose)
Number of subjects: 42
Study 19675499 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) (no treatment)
Number of subjects: 42
Study 17115237 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1 W, 15 Hz, 60 s, two times)
Number of subjects: 9
Study 17115237 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (100 mJ, 3 Hz, 60 s, two times)
Number of subjects: 9
Study 17115237 — intervention group
Group type: COMPARATOR
Intervention: Control group without any treatment
Number of subjects: 9
Study 15559351 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin infusion (2 ampules of oxytocin at 10 u/mL/amp added to 1000 mL saline at 40 mU/min)
Number of subjects: 88
Study 15559351 — intervention group
Group type: COMPARATOR
Intervention: No oxytocin infusion (control group)
Number of subjects: 88
Study 11698316 — intervention group
Group type: EXPERIMENTAL
Intervention: Local administration of meloxicam 7.5 mg
Number of subjects: 56
Study 11698316 — intervention group
Group type: COMPARATOR
Intervention: i.v. administration of meloxicam 7.5 mg
Number of subjects: 56
Study 9383806 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (Leucomax, 5 micrograms/kg) administered subcutaneously for 10 days after chemotherapy
Number of subjects: 8
Study 9383806 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard-dose chemotherapy without GM-CSF)
Number of subjects: 8
Study 8031548 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 309
Study 8031548 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 309
Study 8031548 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 309
Study 8031548 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (added if monotherapy was inadequate)
Number of subjects: 309
Study 8031548 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 309
Study 2902274 — intervention group
Group type: EXPERIMENTAL
Intervention: Caesarean section combined with hepatitis B immunisation
Number of subjects: 447
Study 2902274 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 447
Study 4913962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifuratel (Magmilor)
Number of subjects: 96
Study 4913962 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (Flagyl)
Number of subjects: 96
Study 30755265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (L-type calcium channel antagonist)
Number of subjects: 0
Study 30755265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28199903 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest intervals of 10, 20, and 40 seconds (randomized and counterbalanced)
Number of subjects: 48
Study 28199903 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with CAI
Number of subjects: 48
Study 28199903 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest intervals of 10 to 40 seconds
Number of subjects: 48
Study 28199903 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 48
Study 26289810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent activities coupled with aerobic training (3 sessions of 60 minutes weekly for 8 weeks)
Number of subjects: 24
Study 26289810 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 24292212 — intervention group
Group type: EXPERIMENTAL
Intervention: ERG-positive tumors
Number of subjects: 1243
Study 24292212 — intervention group
Group type: EXPERIMENTAL
Intervention: ERG-negative tumors
Number of subjects: 1243
Study 20882400 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care plus the promotora contextual intervention
Number of subjects: 120
Study 20882400 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care alone
Number of subjects: 120
Study 18165593 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 90 mg orally twice daily
Number of subjects: 92
Study 18165593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 16445320 — intervention group
Group type: EXPERIMENTAL
Intervention: Clo-Sur P.A.D. hemostatic device
Number of subjects: 209
Study 16445320 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual compression
Number of subjects: 209
Study 12492801 — intervention group
Group type: COMPARATOR
Intervention: Esmolol-induced controlled hypotension (CH) alone group (n=15)
Number of subjects: 30
Study 12492801 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol-induced controlled hypotension combined with acute normovolemic hemodilution (E-ANH group, n=15)
Number of subjects: 30
Study 11776116 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 60
Study 11776116 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium
Number of subjects: 60
Study 9298771 — intervention group
Group type: EXPERIMENTAL
Intervention: vVO2max (271 +/- 18 m x min(‐1))
Number of subjects: 6
Study 9298771 — intervention group
Group type: EXPERIMENTAL
Intervention: 92% of vVO2max
Number of subjects: 6
Study 9298771 — intervention group
Group type: COMPARATOR
Intervention: Incremental treadmill test
Number of subjects: 6
Study 8472517 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-679 at 600 mg/die
Number of subjects: 60
Study 8472517 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-679 at 1200 mg/die
Number of subjects: 60
Study 8472517 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-679 at 1800 mg/die
Number of subjects: 60
Study 8472517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (600 mg/die)
Number of subjects: 60
Study 3776982 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading Center evaluations using photographic and visual field data
Number of subjects: 138
Study 3776982 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading Center evaluations with additional information (medical history, refractive error, best corrected visual acuity)
Number of subjects: 138
Study 3776982 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement between Reading Center examiners
Number of subjects: 138
Study 28714323 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Wheelchair Skills Training Program (5 sessions of 30 minutes each)
Number of subjects: 17
Study 28714323 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study 27401364 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg EPA+DHA daily for 52 weeks
Number of subjects: 264
Study 27401364 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg EPA+DHA daily for 52 weeks
Number of subjects: 264
Study 27401364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 24892462 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (saturated fat)
Number of subjects: 47
Study 24892462 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (polyunsaturated fat)
Number of subjects: 47
Study 24892462 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected (ART-naïve)
Number of subjects: 47
Study 24892462 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected (on ART)
Number of subjects: 47
Study 22561774 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine plus hydration with normal saline
Number of subjects: 400
Study 22561774 — intervention group
Group type: COMPARATOR
Intervention: Hydration with normal saline only
Number of subjects: 400
Study 20608252 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate endpoint trials
Number of subjects: 0
Study 20608252 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs approved based on surrogate endpoint trials
Number of subjects: 0
Study 17607084 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative multi-factorial intervention program
Number of subjects: 199
Study 16110227 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient treatment (IP)
Number of subjects: 109
Study 16110227 — intervention group
Group type: COMPARATOR
Intervention: Day hospital treatment
Number of subjects: 109
Study 12390318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 18
Study 12390318 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 9932970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracarotid amobarbital test (IAT)
Number of subjects: 23
Study 7539966 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF
Number of subjects: 20
Study 7539966 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (no G‐CSF)
Number of subjects: 20
Study 2185673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual captopril 12.5 mg
Number of subjects: 40
Study 2185673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual captopril 25 mg
Number of subjects: 40
Study 2185673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2185673 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual captopril (both doses)
Number of subjects: 40
Study 647173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic induction procedure
Number of subjects: 40
Study 647173 — intervention group
Group type: COMPARATOR
Intervention: Motivational instructions
Number of subjects: 40
Study 31648336 — intervention group
Group type: EXPERIMENTAL
Intervention: Lestaurtinib
Number of subjects: 140
Study 31648336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 31648336 — intervention group
Group type: EXPERIMENTAL
Intervention: Flt3L measurement combined with minimal residual disease (MRD) status
Number of subjects: 140